Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: cross-sectional results of a German multicentre observational study (PROSa)

  • Objective. We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST). Methods: In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions. Results: Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = −15.7), role (B = −25.7), social (B = −18.4), and cognitive functioning (B = −19.7); fatigue (B = 15.93); general health (B = −14.23); and EORTC-sum score (B = −13.82) compared to all other patients. Conclusion: The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation.
Metadaten
Author:Martin Eichler, Daniel Pink, Franka Menge, Jens Jakob, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis AndreouORCiDGND, Susanne Singer, Robert Grützmann, Diana I. Dmytrow, Karin Arndt, Armin Tuchscherer, Peter Reichardt, Marit Ahrens, Annegret Kunitz, Johannes Mohm, Martin Bornhäuser, Jochen Maximilian Schmitt, Markus Kajo Schuler
URN:urn:nbn:de:hebis:30:3-639616
DOI:https://doi.org/10.1111/ecc.13484
ISSN:1365-2354
Parent Title (English):European journal of cancer care
Publisher:Wiley-Blackwell
Place of publication:Oxford [u.a.]
Document Type:Article
Language:English
Date of Publication (online):2021/08/03
Date of first Publication:2021/08/03
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/03/24
Tag:clinically important restrictions and symptoms; gastrointestinal stromal tumours; health-relatedquality of life; observational study; rare disease; tyrosine kinase inhibitors
Volume:30
Issue:6, art. e13484
Page Number:15
First Page:1
Last Page:15
Note:
The PROSa study was funded by the German Cancer Aid (No. 111713).
HeBIS-PPN:49469677X
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0